Stifel raises Medtronic stock price target to $95 on strong quarter

Medtronic reported Q1 FY2027 revenue of $9.76B, beating the $9.53B Stifel projection and the $9.55B consensus, with organic growth of 13.7% (vs ~7% excluding a 670 bps extra selling-week benefit). EPS rose to $1.45, above $1.39 expectations, aided by a tariff tax refund contributing ~$0.03. Management raised full-year FY2027 revenue and EPS guidance, prompting multiple analysts to lift price targets (e.g., Stifel to $95, BofA to $110, Wells Fargo to $104), while the stock’s 3.13% dividend yield and 50-year dividend streak support shareholder appeal.

Analysis

The important read-through is not the headline beat; it is that Medtronic appears to be re-accelerating in a few high-margin franchises at the same time, which reduces the market’s willingness to value it as a slow-growth dividend utility. That matters most for BSX and, to a lesser extent, other procedure-driven medtech names: when a large incumbent posts credible strength in cardiac ablation and diabetes, it validates end-demand rather than just pricing power, and that usually pulls forward capital allocation into the whole category.

The quality of the beat is mixed, though. A meaningful share of the growth signal is likely transitory, so the next 1-2 quarters will determine whether this is a new operating regime or just a clean comp/extra-week burst. If the normalized ex-week run rate stays in the high-single-digits, the stock can earn a better multiple; if it reverts toward mid-single-digits, the current analyst target resets will look like the ceiling rather than the floor.

Contrarian view: the market may be underestimating how much of the upside is already funded by the dividend and existing rerating, especially with rates still elevated. The stock is probably better viewed as a quality compounder than a fresh growth story, which caps upside unless management sustains guidance through the next two prints. The clearest falsifier is any evidence that the cardiac ablation surge was channel timing rather than durable procedure share.

For positioning, this is a decent tactical long on pullbacks, but not a conviction sector breakout. The better risk/reward is to own MDT into the next earnings cycle while fading names where the market is already pricing a similar growth inflection without the same dividend support or guidance credibility.

Key Decisions for Investors

• Buy MDT on any post-open weakness; 1-3 month hold with a 5-8% upside target if management sustains high-single-digit organic growth ex-transitory items. Stop if the next quarter’s normalized growth slips back toward mid-single digits.
• Use a call spread rather than outright stock if implied volatility stays elevated: MDT 3-6 month call spread centered around the current trading area to express modest rerating, not a blowout move.
• Add BSX to the watchlist as the cleaner second-order winner from validation of the ablation category; if BSX management commentary confirms similar demand strength, it supports a sector-wide rerating over the next 1-2 quarters.
• Avoid chasing a broad medtech basket at this stage; prefer MDT as the idiosyncratic name because the dividend and guidance raise provide downside support that IHI/XLV won’t isolate.
• If long MDT, set a review trigger on the next earnings print: if management excludes the extra-week effect and still guides to only low-single-digit organic growth, take profits and reassess the multiple expansion thesis.